January 2018

Satipharm’s CBD capsules. The reintroduction of medical cannabis into treating illness and disease has received a boost, courtesy of clinical trials being conducted by MMJ PhytoTech (ASX: MMJ). In an update to shareholders, MMJ has published an update regarding the ongoing Phase 2 clinical trial of its Satipharm CBD capsules. From the results made available […]

by

Satipharm’s CBD capsules. The reintroduction of medical cannabis into treating illness and disease has received a boost, courtesy of clinical trials being conducted by MMJ PhytoTech (ASX: MMJ). In an update to shareholders, MMJ has published an update regarding the ongoing Phase 2 clinical trial of its Satipharm CBD capsules. From the results made available […]

by

(October 25, 2017 / JNS) In a development that could spark Israel’s latest groundbreaking achievement within the medical cannabis sector, the Israeli-British cannabis biotech start-up CIITECH announced Oct. 24 that it will fund a research project in collaboration with the Hebrew University of Jerusalem exploring methods for treating asthma with medical cannabis. Asthma, a pervasive […]

by

While a number of studies have suggested that marijuana may be effective for reducing seizures, new research cautions that potent and synthetic forms of the drug have the opposite effect. Researchers suggest that the use of potent cannabinoids have the potential to trigger seizures. Researchers from the University of Tsukuba in Japan found that natural tetrahydrocannabinol […]

by

New Zealand’s Hikurangi Hemp says it’s on track for several firsts in the country – the first medical cannabis producer, the first to conduct a clinical trial and the first to sell a product with the government’s stamp of approval – and it will soon look to investors. Hikurangi Hemp is focusing on the non-psychoactive […]

by

One of the storied families of greater Maple Valley are the Peacocks of Hobart. In this photo from the late 1890s, the Peacock family pose in front of the home they built in 1889. Charles and Ellen were born in England in 1851, married at age 20, and immigrated to the U.S. by way of […]

by

Source: Shutterstock/Malyshev Oleg TREATMENT WITH PHARMACEUTICAL variants of cannabidiol could reduce fall-related seizures in treatment-resistant epilepsy sufferers, according to new research. People with Lennox-Gastaut syndrome, a severe and lifelong form of childhood-onset epilepsy, who had previously been found to be resistant to conventional treatments, were found to have benefitted from such treatment according to a […]

by

LONDON and CARLSBAD, Calif., Dec. 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced it has submitted its Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Epidiolex® (cannabidiol or […]

by

Source: Shutterstock/Malyshev Oleg TREATMENT WITH PHARMACEUTICAL variants of cannabidiol could reduce fall-related seizures in treatment-resistant epilepsy sufferers, according to new research. People with Lennox-Gastaut syndrome, a severe and lifelong form of childhood-onset epilepsy, who had previously been found to be resistant to conventional treatments, were found to have benefitted from such treatment according to a […]

by

Source: Shutterstock/Malyshev Oleg TREATMENT WITH PHARMACEUTICAL variants of cannabidiol could reduce fall-related seizures in treatment-resistant epilepsy sufferers, according to new research. People with Lennox-Gastaut syndrome, a severe and lifelong form of childhood-onset epilepsy, who had previously been found to be resistant to conventional treatments, were found to have benefitted from such treatment according to a […]

by

Dutch regulators have signed off on AXIM Biotechnologies’ clinical trial plans for a chewing gum that offers controlled release of cannabinoids to treat multiple sclerosis patients’ pain and spasticity. The Dutch Medicines Evaluation Board’s sign-off on MedChew Rx means AXIM can start trials. A leader in cannabinoid research, New York-based AXIM is developing 16 cannabinoid-based pharmaceutical, nutrition and cosmetic […]

by